HuGE Literature Finder
Records
1
-
25
Use of proteomics to identify mechanisms of hepatocellular carcinoma with the CYP2D6*10 polymorphism and identification of ANGPTL6 as a new diagnostic and prognostic biomarker. Journal of translational medicine 2021 Aug 19 (1): 359. Hu Guiming, Gao Fei, Wang Guanzhe, Fang Yan, Guo Yuanyuan, Zhou Jun, Gu Yuhan, Zhang Cunzhen, Gao Na, Wen Qiang, Qiao Haili |
Genomic Sequencing of Cancer-related Genes in Sinonasal Squamous Cell Carcinoma and Coexisting Inverted Papilloma. Anticancer research 2021 Jan 41 (1): 71-79. Uchi Ryutaro, Jiromaru Rina, Yasumatsu Ryuji, Yamamoto Hidetaka, Hongo Takahiro, Manako Tomomi, Sato Kuniaki, Hashimoto Kazuki, Wakasaki Takahiro, Matsuo Mioko, Nakagawa Takas |
Estrogen Metabolism-Associated CYP2D6 and IL6-174G/C Polymorphisms in Schistosoma haematobium Infection. International journal of molecular sciences 2017 Nov 18 (12): . Cardoso Rita, Lacerda Pedro C, Costa Paulo P, Machado Ana, Carvalho André, Bordalo Adriano, Fernandes Ruben, Soares Raquel, Richter Joachim, Alves Helena, Botelho Monica |
Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma. Oncotarget 2016 May . Zhou Jun, Wen Qiang, Li Sai-Fei, Zhang Yun-Fei, Gao Na, Tian Xin, Fang Yan, Gao Jie, Cui Ming-Zhu, He Xiao-Pei, Jia Lin-Jing, Jin Han, Qiao Hai-Li |
Family history of cancer and the risk of squamous cell carcinoma of oesophagus: a case-control study in Kashmir, India. British journal of cancer 2015 Jul 113 (3): 524-32. Bhat G A, Shah I A, Rafiq R, Nabi S, Iqbal B, Lone M M, Islami F, Boffetta P, Dar N |
Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using The Cancer Genome Atlas data. Pharmacogenetics and genomics 2015 Jan 25 (1): 1-7. Kim In-Wha, Han Nayoung, Kim Myeong Gyu, Kim Therasa, Oh Jung |
Risk of renal cell carcinoma and polymorphism in phase I xenobiotic metabolizing CYP1A1 and CYP2D6 enzymes. Urologic oncology 2013 Oct 31 (7): 1350-7. Ahmad Shiekh Tanveer, Arjumand Wani, Seth Amlesh, Nafees Sana, Rashid Summya, Ali Nemat, Hamiza Oday O, Sultana Sarw |
CYP2A6, CYP1A1, and CYP2D6 polymorphisms in lung cancer patients from central south China. Medical oncology (Northwood, London, England) 2013 Jun 30 (2): 521. Huang Feng-mao, Chen Han-chun, Khan Md Asaduzzaman, Yang Fu-lan, Wan Xin-xing, Xu Ai-hua, Ou-yang Fang-dan, Zhang Dian-zhe |
CYP2D6*4 allele and breast cancer risk: is there any association? Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2012 Feb 14 (2): 157-9. Fernández-Santander Ana, del Saz Sánchez Miguel, Tejerina Gómez Armando, Bandrés Moya Fernan |
Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2011 Feb 32 (1): 215-22. Luo Ya-Ping, Chen Han-Chun, Khan Md Asaduzzaman, Chen Fang-Zhi, Wan Xin-Xing, Tan Bo, Ou-Yang Fang-Dan, Zhang Dian-Zhe |
Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 genotypes modify the susceptibility to head and neck cancer and treatment response. Mutation research 2010 Feb 684 (1-2): 49-55. Yadav Sunishtha S, Ruwali Munindra, Pant Mohan C, Shukla Pragya, Singh Ram L, Parmar Devend |
Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma. BMC cancer 2008 8 (1): 109. Khedhaier Achraf, Hassen Elham, Bouaouina Noureddine, Gabbouj Sallouha, Ahmed Slim Ben, Chouchane Lot |
Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma. Journal of gastroenterology and hepatology 2005 Aug 20 (8): 1191-7. Mochizuki J, Murakami S, Sanjo A, Takagi I, Akizuki S, Ohnishi A |
CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutation research 2005 Jul 574 (1-2): 112-23. Gajecka Marzena, Rydzanicz Malgorzata, Jaskula-Sztul Renata, Kujawski Maciej, Szyfter Witold, Szyfter Krzyszt |
Gene polymorphisms in detoxification enzymes as susceptibility factor for head and neck cancer? Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2003 May 128 (5): 674-80. Gronau S, Koenig-Greger D, Jerg M, Riechelmann |
CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. International journal of cancer. Journal international du cancer 2003 Apr 104 (3): 310-7. Silvestri Laura, Sonzogni Laura, De Silvestri Annalisa, Gritti Chiara, Foti Luciana, Zavaglia Claudio, Leveri Michela, Cividini Agostino, Mondelli Mario U, Civardi Emilio, Silini Enrico |
[First results on the influence of polymorphisms at glutathione S-transferase, cytochrome P450, and tumor necrosis factor gene loci on the development of multiple head and neck cancer]. Laryngo- rhino- otologie 2003 Jan 82 (1): 25-30. Matthias C, Jahnke V, Fryer A A, Strange R |
[Influence of glutathione s-transferase and cytochrome p450 polymorphisms on prognosis of head and neck cancer]. Laryngo- rhino- otologie 2002 Jun 81 (6): 406-12. Matthias C, Jahnke V, Fryer A A, Strange R |
Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumour suppressor gene transversions in sporadic renal cell carcinoma. Pharmacogenetics 2001 Aug 11 (6): 521-35. Gallou C, Longuemaux S, Deloménie C, Méjean A, Martin N, Martinet S, Palais G, Bouvier R, Droz D, Krishnamoorthy R, Junien C, Béroud C, Dupret J |
Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. International journal of cancer. Journal international du cancer 2001 Apr 92 (2): 220-5. Krajinovic M, Ghadirian P, Richer C, Sinnett H, Gandini S, Perret C, Lacroix A, Labuda D, Sinnett D |
Association of Genetic Variants of CYP2C19 and CYP2D6 with Esophageal Squamous Cell Carcinoma Risk in Northern India, Kashmir. Nutrition and cancer 0 69 (4): 585-592. Bhat Gulzar Ahmad, Bhat Arshid Bashir, Lone Mohd Maqbool, Dar Nazir Ahm |
CYP 2D6 polymorphism: a predictor of susceptibility and response to chemoradiotherapy in head and neck cancer. Journal of cancer research and therapeutics 0 8 (1): 40-5. Shukla Pragya, Gupta Deepak, Pant Mohan Chand, Parmar Devend |
CYP1A1 and CYP2D6 polymorphism and risk of lung cancer in a North Indian population. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 0 8 (5): 415-28. Sobti R C, Sharma S, Joshi A, Jindal S K, Janmeja |
Impact of ABCB1 and CYP2D6 polymorphisms on tamoxifen treatment outcomes and adverse events in breast cancer patients. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 0 22 (5): 1217-1226. Argalacsova Sona, Slanar Ondrej, Bakhouche Hana, Pertuzelka Lub |
Polymorphism of the CYP2D6 gene in women with breast cancer treated with tamoxifen. European journal of gynaecological oncology 0 37 (5): 700-702. de Vasconcelos-Valenca R J, Melo M A, Lima E, de Sousa G V, Nazario A C, da Siilva B |
- Page last reviewed:Jul 25, 2022
- Page last updated:Jan 26, 2023
- Content source: